Elacestrant (Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial

June 17, 2022 | Aditya Bardia, MD, MPH

Share on:
View More
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    View More
    Current Time 0:00
    Duration 0:00
    Loaded: 0%
    Stream Type LIVE
    Remaining Time 0:00
     
    1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Dr Aditya Bardia reviews recently published data from the EMERALD trial on elacestrant versus endocrine therapy in patients with ER-positive/HER2-negative (ER+/HER2–) breast cancer.
      Funding supported by Stemline Therapeutics. Content independently developed by OncLive.